The aim of the present study was to determine whether a prostate-specific amplicon, containing a probasin-derived promoter (ARR 2 PB) upstream of an essential Herpes simplex virus-1 (HSV-1) viral gene, infected-cell polypeptide 4 (ICP4), could complement an HSV-1 helper virus with this gene deleted (ICP4 À ) and cause lytic replication specifically in prostate cancer cells. Two amplicon constructs, CMV-ICP4 and ARR 2 PB-ICP4, were packaged by a replication-deficient ICP4
Introduction
Prostate cancer is the most commonly diagnosed non-skin cancer in men and the second leading cause of cancer deaths in men. 1 It is estimated that over 234 000 men in North America will develop prostate cancer and approximately 27 000 will die from this disease. 2 If caught early, when still confined to the prostate, it is frequently curable by surgery or radiotherapy. However, patients who present with metastatic disease have concomitantly fewer curative treatment options and a median life expectancy of o3 years. [3] [4] [5] The primary treatment for locally advanced, recurrent or metastatic prostate cancer is usually some form of androgen ablation therapy. 6, 7 Unfortunately, the effectiveness of androgen withdrawal therapy in advanced prostate cancer is restricted to a duration of about 18-24 months due to progression of tumor cells. [8] [9] [10] At this lethal end phase, even with the most effective chemotherapy regimens, median survival is only around 19 months. 11, 12 Clearly, if we are to have an impact on patient survival, more effective, new approaches for dealing with advanced disease are required. In this regard, gene therapy offers a promising therapeutic option for treating locally advanced, recurrent and metastatic AI prostate cancer (for reviews, see Satoh and co-workers [13] [14] [15] ). Prostate cancer lends itself to gene therapy since the prostate is not essential for sustaining life and therefore can be ablated, plus intraprostatic administration of gene therapy via transurethral, transperineal and transrectal routes is technically easy. 16 Another advantage is that there are several prostatespecific promoters available which allow for tissuespecific targeting.
Herpes simplex virus type 1 (HSV-1) has a number of favorable features that make it an attractive viral vector for cancer treatment, and various forms of replicationdefective or replication-conditional vectors have been developed for cancer therapy. 17 G207, an example of this type of recombinant HSV-1, has been shown to be efficacious in treating malignant glioma 18 and is being evaluated in clinical trials. 19 Other replication-competent HSV-1 vectors are also currently being tested in human clinical trials for treatment of malignant melanoma, 20 breast cancer, 21 head and neck cancer 22 and metastasis from colorectal cancer. 23 Results from the above phase I clinical trials have demonstrated that HSV-1 viral therapy was well tolerated by patients and has shown efficacy in some cases.
HSV-1 virus is a double-stranded DNA virus with a genome size of approximately 152 kb encoding more than 84 genes. The viral genes are divided into three categories: immediate early (IE), early (E) and late (L) genes. There are five IE genes: infected-cell protein 0 (ICP0), infectedcell protein 4 (ICP4), infected-cell protein 22 (ICP22), infected-cell protein 27 (ICP27) and infected-cell protein 47 (ICP47). Among them, ICP4 and ICP27 are absolutely essential for viral replication. The virus enters host cells via cell receptor-mediated endocytosis and once in the cell, the tegument protein viral protein 16 (VP16) and the viral DNA are transported into the nucleus where viral genes are expressed in a coordinately regulated and sequentially ordered manner. 24 Inside the nucleus, VP16 stimulates the transcription of IE genes, whose products are involved in transcription regulation and stimulation of the expression of E genes, which primarily encode enzymes involved in nucleotide metabolism and viral-DNA replication. Upon viral-DNA replication initiation, expression of L genes commences. L genes mainly code for structural components of the virion. 25 At the end of the replication cascade, mature viral particles are assembled and released from the host cell, resulting in cell lysis and cell death.
Tissue-specific and tumor-specific control of the expression of viral genes essential for replication could potentially regulate oncolytic virus replication differentially, and therefore, result in selective killing of cancer cells. We hypothesized that a replication defective HSV-1 mutant lacking one of the essential genes may become oncolytic when the missing gene is supplemented by a coexisting amplicon expressing this viral gene in a celltype specific fashion. To test this hypothesis, an HSV-1 amplicon structure was constructed containing a prostatespecific promoter inserted in front of the ICP4 gene. 26 The helper virus used in this study is a replication-deficient recombinant ICP4
À helper virus (CgalD3) which has had both copies of the ICP4 gene deleted and an insertion of the bacterial b-galactosidase gene in the ICP6 gene locus. 27 The helper virus carries all other necessary genes for viral replication except the ICP4 gene, and therefore, it cannot replicate except in the presence of a complementing cell line transfected with ICP4 gene or coinfected with an amplicon virus expressing this gene. The amplicon virus carries both a viral origin of replication and a packaging signal, which allow the construct to replicate and be packaged by the helper HSV-1 virus in host cells. 28 ARR 2 PB is a small composite promoter derived from the prostate-specific rat probasin promoter that has been reported to be expressed in a highly prostate-specific manner in transgenic mice. 26, 29, 30 This androgen-responsive promoter has also been shown to direct prostatespecific expression of EGFP and herpes thymidine kinase in human prostate cancer cell lines both in vitro and in vivo using a lentiviral vector system. 31, 32 In the present study, our results demonstrated that the expression of ICP4 gene under a prostate-specific promoter in an amplicon virus complemented the ICP4 À helper virus to enable viral replication and subsequently led to oncolysis of LNCaP human prostate cancer cells both in vitro and in vivo.
Materials and methods

Plasmid preparation
The ARR 2 PB-ICP4 plasmid was constructed and described by Yang et al. 33 The CMV-ICP4 plasmid was made by replacing the ARR 2 PB promoter (465 bp) of the ARR 2 PB-ICP4 plasmid with the CMV promoter (605 bp), which was excised from the plasmid pHR-CMV-EGFP at ClaI-BamHI sites. The structure of the two amplicon plasmids is represented in Figure 1 .
Cell culture conditions
Vero and its derivative cell line, 7B (transfected to express ICP4 and ICP27) cells, were grown in Dulbecco's modified Eagle medium (DMEM) supplemented with 5% fetal bovine serum (FBS) and antibiotics (penicillin and streptomycin). LNCaP prostate cancer cells were grown in DMEM supplemented with 10% FBS and antibiotics. For androgen-regulation experiments, LNCaP cells were maintained in DMEM with 10% charcoal-stripped FBS with or without the addition of 10 nM R1881, a synthetic androgen. All cells were maintained in a 5% CO 2 incubator at 371C.
Viral preparation
The replication-deficient ICP4 À helper virus, CgalD3 27 was a gift from Dr Paul Johnson (Neurovir Inc., Vancouver, BC, Canada) and was propagated and tittered in 7B cells. 33, 34 Briefly, 7B cells were infected with ICP4
À helper virus at a multiplicity of infection (MOI) of 0.1. Two days after viral infection, cells were scarped from the plates and the medium containing both ICP4 À helper virus and 7B cells was subjected to three freeze-thaw cycles in order to lyse 7B cells and to release intracellular viral particles. The cell debris was then precipitated by centrifuging at 3200 Â g for 5 min (Thermo IEC Centra CL3/CL3R) and the viral supernatant tittered on 7B cells. Figure 1 Structure of the two-amplicon plasmids used in these studies. The CMV-ICP4 amplicon is a constitutive, non-tissue selective complementing amplicon whereas the ARR 2 PB-ICP4 amplicon is an androgen-regulated, prostate-specific complementing amplicon.
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For amplicon virus production, 7B cells were grown in 100 mm cultural dish containing DMEM with 10% FBS without antibiotics 1 day before transfection. Monolayer of 90B95% confluent 7B cells was transfected with 24 mg of the CMV-ICP4 or ARR 2 PB-ICP4 plasmid DNA using the Lipofectamine 2000 (Invitrogen, Vancouver, BC, Canada) according to the manufacturer's instruction. At 24 h after transfection, the 7B cells were superinfected with the ICP4
À helper virus at an MOI of 1. Three days after the superinfection, viral supernatant was collected as described above and subjected to further viral amplification by infecting more plates of 7B cells. Finally, the stock virus produced was a mixture of helper and amplicon viruses, and is referred to as CMV-ICP4 amplicon/helper virus and ARR 2 PB-ICP4 amplicon/helper virus. The virus titer was determined using 7B cells. The helper/ amplicon ratio was determined by quantitative real-time PCR analysis using ICP0 primers ( 
Viral infection
LNCaP cells 35 were seeded in 6-well plates at a density of 3.5 Â 10 5 cells/well in 2 ml of DMEM medium with 10% charcoal-stripped FBS. After 3 days, the LNCaP cells were infected with ICP4
À helper virus, CMV-ICP4 amplicon/helper virus, or ARR 2 PB-ICP4 amplicon/helper virus at an MOI of 1 and incubated at 371C for 1 h. The medium was then replaced with 2 ml DMEM plus 10% charcoal-stripped FBS with or without R1881 (10 nM). The supernatant was collected and tittered for virus production on 7B cells at 48 or 72 h after infection as described above. The total RNA was extracted from the infected cells at 16 h after infection by Trizol and subjected to one-step reverse transcriptase-PCR (RT-PCR) analysis.
Cell viability assay
LNCaP cells were seeded in 96-well plates at a density of 3 Â 10 4 cells/well in 50 ml medium and then infected with CMV-ICP4 or ARR 2 PB-ICP4 amplicon/helper virus at helper virus MOI of 1 on the following day. After 48, 72, 96 and 120 h of viral infection, live cells were measured by an MTT assay (Cell Proliferation Kit 1; Roche Diagnostics, Indianapolis, IN, USA) for cell viability according to the manufacturer's instructions. 36 LNCaP xenograft experiments Athymic nude mice were purchased from Harlan Sprague Dawley (Indianapolis, IN, USA) and LNCaP cancer cells were implanted subcutaneously by injecting 5 Â 10 6 cells in 100 ml of medium with matrigel at four different sites over the shoulders and hind legs on both sides. Animals were monitored for tumor development two times a week by palpation of the injection sites. When detected, tumor volumes were determined by caliper measurements and calculated using the formula volume ¼ width Â length Â thickness Â p/6. When the tumor volume reached approximately 100 mm 3 (at B1-1.5 month after tumor inoculation), the mice were treated with two intratumoral injections (second injection at 1 week after first injection) of medium alone, or of 2 Â 10 6 PFU of the ICP4 À helper virus, CMV-ICP4 amplicon/ helper virus, or ARR 2 PB-ICP4 amplicon/helper virus. Blood was collected by tail-vein bleeding method at days 0, 7 and 14, and the prostate specific antigen (PSA) level from the serum was determined using the Abbott's kits for total PSA MEIA assays on the IMx system. At the end of the treatment period, mice were killed using CO 2 asphyxiation, and selected organs (kidney, liver) and the tumors were removed and analyzed. Statistical significance between different treatment groups was determined by Student's t-test. 33 For the study of ARR 2 PB-ICP4 amplicon/helper virus replication in vivo, a single intratumoral injection of 2 Â 10 6 PFU ARR 2 PB-ICP4 amplicon/helper virus was administered and tumors were excised from the mice at day 7 (early stage, n ¼ 4) and day 14 (late stage, n ¼ 3). The virus was liberated from the tumors by homogenization in PBS and the virus titer was determined by plaque forming assays on 7B cells. All experimental procedures were approved by the UBC Animal Care Committee and followed the guidelines and policies of the Canadian Council on Animal Care.
DNA, RNA isolation and qRT-PCR
Total RNA was extracted from LNCaP cells infected with ARR 2 PB-ICP4 amplicon/helper virus using Trizol (Invitrogen) following manufacturer's protocol. Two micrograms of RNA was then converted into cDNA in the one-step RT-PCRs. Organs collected from mice were subjected to three freeze-thaw cycles, cut into small pieces and homogenized in 1 Â PBS buffer using a 2 ml dounce homogenizer. DNA was extracted from the homogenate using the phenol-chloroform extraction method. 37 Oligonucleotide primers for ICP0 gene (5 0 -TTACGTGAACAA GACTATCACGGG-3 0 and 5 0 -TCCATGTCCAGGATGG GC-3 0 ), ICP4 gene (5 0 -GGCCTGCTTCCGGATCTC-3 0 and 5 0 -GGTGATGAAGGAGCTGCT GTT-3 0 ) and b-actin gene (5 0 -ACGAGGCCCAGAGCAAGAG-3 0 and 5 0 -TCTC CATGTCGTCCCAGTTG-3 0 ) were designed for one-step RT-PCR and Q-PCR using the Primer Express 2.0 software (Applied Biosystems, Foster City, CA, USA). All real-time PCR were performed in 25 ml SYBR-green mixture containing the MultiScribe Reverse Transcriptase using the ABI prism 7000 Sequence Detection System (Applied Biosystems). ICP4 mRNA level was first normalized to b-actin mRNA and then compared with the control group (LNCaP infection with ICP4 À helper virus). DNA copy number was normalized to a standard curve prepared from the stock viral DNA according to the manufacturer's protocols.
Histochemical staining
Harvested tissues were embedded in optimal cutting temperature compound and 10 mm sections were subjected to X-gal staining. 38 . Briefly, the sections were fixed with 4% paraformaldehyde for 15 min, washed once with 1 Â PBS for 5 min, and then incubated with 4% X-gal substrate (Invitrogen) in LacZ buffer overnight at 371C. The following day, the sections were stained with Eosin and pictures were taken using a light microscope.
Results
Prostate-specific expression of ICP4 complements the replication of HSV-1 ICP4 À helper virus in LNCaP prostate cancer cells in vitro To test the androgen-responsiveness and the complementing ability of the amplicons to aide in ICP4 À helper virus replication, LNCaP human prostate cancer cells 35 were infected with ICP4 À helper virus alone or ARR 2 PB-ICP4 (Figure 1 ) at an MOI of 1 (an input virus amount of B5 Â 10 5 PFU) in the presence or absence of 10 nM of the synthetic androgen, R1881. The virus titer at 72 h post-infection was determined by plaque forming assays on 7B cells (Figure 2a) . The results showed that the ICP4 À helper virus alone was incapable of replicating in LNCaP cells, in keeping with the fact that it lacks the essential IE gene ICP4, whereas both the CMV-ICP4 and ARR 2 PB-ICP4 amplicons were able to complement the ICP4 À helper virus to enable its replication in LNCaP cells. Addition of 10 nM of the potent androgen R1881 significantly increased virus titers (t-test, Po0.01) by 42-fold from 2.3071.69 Â 10 6 to 5.8870.85 Â 10 6 PFU/ ml for experiments with the ARR 2 PB-ICP4 amplicon/ helper virus but had no effect when the CMV-ICP4 amplicon/helper virus was used. Consistently, ICP4 mRNA was 43-fold higher in the presence of 10 nM R1881 (41.172.5) as compared to no androgen treatment (13.472.0) (mean7s.d., n ¼ 4, Po0.01). This is in keeping with the fact that the ARR 2 PB promoter contains two copies of androgen response elements and is, thus, very androgen responsive. 26 We next determined whether viral replication was dependent on the ratio of helper virus to amplicon. LNCaP cells were infected with ARR 2 PB-ICP4 amplicon together with helper virus at various helper virus to amplicon ratios (50:1, 100:1, 200:1, 400:1, 800:1, 1600:1) at a final helper virus MOI of 1 in the presence of 10 nM R1881. As shown in Figure 2b , virus replication was acutely dependent on the helper to amplicon ratio with an approximately 3.6 and 6-fold increase in the virus titer at a ratio of 50:1 as compared to the virus titer at ratios of 100:1 and 200:1, respectively (5.8870.85 Â 10 6 vs 1.6470.49 Â 10 6 and 0.9570.27 Â 10 6 PFU/ml; Po0.001). It was necessary to confirm that replication of ICP4 À helper virus was solely dependent on the ARR 2 PB-ICP4 amplicon and not caused by a reversion to wild-type virus through a recombination event due to the presence of homologous regions (such as OriS and packaging sequence) contained in both the ARR 2 PB-ICP4 amplicon construct and the ICP4 À helper virus. Accordingly, we infected 7B and Vero cells with the ARR 2 PB-ICP4 amplicon/helper virus stock at various MOIs from 1 to 10 À6 . The ICP4 À helper virus can grow in 7B cells but not in Vero cells, while any recombinant wild-type revertants will grow in both. We speculated that since the amplicon and helper virus must be in the same cell to allow the helper virus to replicate, then by reducing the MOI, the probability of coexistence of both in the same cell would decline to near zero. We found that approximately 1 in 10 amplicons from a stock with a helper to amplicon ratio of 50:1 will infect the same cells with the helper virus enabling the formation of plaques. As expected, no plaques were seen when cells were infected with viral stock at an MOI o10 À5 (data not shown). These results support the conclusion that replication of helper virus was entirely dependent on the presence of the amplicon and that no recombinant virus was generated during the preparation of viral stock solutions. Taken together, our results indicated that prostate-specific expression of ICP4 by an amplicon complemented the ICP4 À helper virus, enabling it to replicate in LNCaP cells, and that with the ARR 2 PB-ICP4 amplicon, viral replication was androgenresponsive and dependent on the relative amount of amplicon present in the viral infectant. (Figure 3b ). More than a 10-fold increase in the virus number was measured at 72 h post-infection, with titers of 5.87570.854 Â 10 6 and 2.18870.178 Â 10 6 PFU/ml for ARR 2 PB-ICP4 and CMV-ICP4 amplicons, respectively.
ARR 2 PB-ICP4 amplicon/helper virus inhibits growth of LNCaP tumor xenografts
Since the ARR 2 PB-ICP4 amplicon/helper virus combination was able to replicate efficiently and kill LNCaP cells in vitro, we next tested the therapeutic efficacy of using this amplicon and helper virus in vivo with the LNCaP xenograft tumor/nude mouse model. When subcutaneous LNCaP tumors grew to approximately 100 mm 3 on the flanks of nude mice, two intratumoral viral injections, totaling 2 Â 10 6 PFU viruses, were administered. Subsequently, the size of each tumor was monitored by caliper measurements once every 2 days, and the fold change in tumor size for each group was determined by comparing the tumor size at each day to the original size at Day 0 (Figure 4a ). For the control groups treated with either DMEM medium alone or ICP4
À helper virus alone, a 3-and 3.5-fold increase in tumor size was observed, respectively, at day 22 post-viral treatment. In contrast, mice treated with the CMV-ICP4 and ARR 2 PB-ICP4 amplicon/helper viruses showed greater than 75% reduction in tumor size at day 16 and at day 20 post-viral treatment, respectively (Po0.01). These results were consistent with the changes in serum PSA levels (Figure 4b) , with an approximately 2.5-fold increase in mice treated with ICP4
À helper virus and a 480% reduction in the serum PSA of mice treated with ARR 2 PB-ICP4 amplicon/helper virus (Po0.05).
The CMV-ICP4 amplicon/helper virus was highly toxic to the mice as the animals exhibited herpetic lesions on the skin around the viral injection area and had severe hemorrhage in the stomach. As well, two mice in this group died on day 10 and the remainder died on day 16 post-inoculation. By comparison, considerably less toxicity was observed in ARR 2 PB amplicon-/helper virustreated animals. No skin lesions were seen in any of these animals, but stomatitis was evident in two out of five animals, resulting in delayed death on day 16 and day 20 post-infection.
To assess viral replication within the LNCaP tumor mass in vivo, a total of 2 Â 10 6 PFU of ARR 2 PB-ICP4 amplicon/helper virus was administered intratumorally in a single dose. Tumors were excised from the mice at day 3 (early stage) and day 5 (late stage) post-viral injection, and the virus was extracted from homogenized tumors. Virus titer (PFU/mg tissue) was determined by plaque assays on 7B cells (Figure 4c) . At an early stage after viral injection, there was a twofold decrease in the amount of virus within LNCaP tumors compared with the amount of input virus, whereas a 410-fold increase was observed at a later stage relative to input virus (Po0.05). This indicated that ARR 2 PB-ICP4 amplicon/helper virus was able to replicate within the LNCaP tumors in vivo. 
ICP4
À helper virus carries the bacterial LacZ gene that encodes b-galactosidase, which can convert the X-gal substrate into a blue form detectable under the microscope expression. In the tumors, high levels of b-galactosidase activity were detected in animals treated with either CMV-ICP4 or ARR 2 PB-ICP4 amplicon/ helper virus. As well, substantial amounts of X-gal staining were evident in both kidney and liver from animals treated with the CMV-ICP4, but not with the ARR 2 PB-ICP4 amplicon/helper virus ( Figure 5 ).
Viral DNA in kidney and liver, as well as in the tumor mass, was also identified and quantified by real-time quantitative PCR using the organs collected from mice treated with amplicons and helper viruses at the termination of the experiments (Table 1 ). Viral sequences were detected by Q-PCR in the kidneys and livers from animals infected with CMV-ICP4 or ARR 2 PB-ICP4 amplicon/ helper viruses. While there was a large variation in estimates of viral DNA copy number by Q-PCR analysis among the samples, higher copy numbers were consistently found in CMV-ICP4 amplicon-/helper virus-treated animals.
Discussion
The main objective of this study was to determine whether we could selectively direct or restrict the oncolytic activity of a mutated herpes virus to prostate cancer cells by combining it with an amplicon virus which expressed the complementing wild-type gene under a prostate-specific promoter. To achieve this, we exploited the HSV-1 helper virus/amplicon system by inserting the prostate-specific and AR-regulated ARR 2 PB promoter in front of ICP4, an essential viral gene, in an amplicon to limit its expression to only prostate-derived cells, so that in the presence of ICP4 À helper virus, lytic viral replication and selective cell killing could only occur in these cells. The HSV-1 amplicon virus contains a HSV-1 replication origin (oriS), a packaging signal sequence, a transgene of interest, and can be packaged into infectious HSV-1 virions in the presence of a transactivating helper virus. 39, 40 We constructed two amplicon viruses: CMV-ICP4, a constitutively active, non-tissue selective complementing amplicon; and ARR 2 PB-ICP4, an AR-enhanced, prostate-specific complementing amplicon (Figure 1) .
We tested the complementing ability of the amplicon viruses to aid in viral replication of the helper virus in LNCaP cells in the presence or absence of the potent, synthetic androgen, 1881. As previously reported, 41 the replication-defective ICP4 À helper virus alone was unable to replicate in the LNCaP cells, but either of the amplicon viruses, CMV-ICP4 or ARR 2 PB-ICP4, was able to complement the replication of the helper virus in LNCaP cells. In LNCaP cells grown in vitro, CMV-ICP4 amplicon/helper virus was refractory to the addition of androgen, whereas the ARR 2 PB-ICP4 amplicon/helper virus infection was androgen responsive such that at 72 h (Figure 2b ). To test this further, both 7B (ICP4 þ ) and its parental cell line Vero cells (ICP4 À ) were infected with the same stock of CMV-ICP4 amplicon/helper virus and the helper/amplicon ratios in both cells were measured 48 h after initial infection with the same titer. Interestingly, the ratio of helper/amplicon was reduced significantly in Vero cells but not in 7B cells (data not shown). It is apparent that the dependency of ICP4-expressing amplicon for viral replication generates a selection pressure that is in favor of growth of amplicon since there were approximately 50 helper viruses for each amplicon in the initial virus stock and only those cells infected with both helper and the amplicon were permissive for viral replication. Given the reverse correlation between the ratio of helper/amplicon and the oncolytic cytotoxicity of this virus (Figure 2 and  3) , the progressively increased proportion of the amplicon after initial inoculation may enhance the efficiency of the helper/amplicon mixture for tumor lysis when the amplicon complements the helper virus replication in a tumor-specific fashion. To determine the potential therapeutic efficacy and relative toxicity of the ARR 2 PB-ICP4 amplicon/helper virus treatments, we performed in vivo studies using the LNCaP xenograft/nude mouse model. 31 The ARR 2 PB-ICP4 amplicon/helper virus was as effective as the CMV-ICP4 amplicon/helper virus in terms of inhibiting the LNCaP tumor growth, whereas when used alone, the ICP4 À helper virus had no effect, which is consistent with the fact that the ICP4 À helper virus is a replication-defective virus incapable of killing tumor cells (Figure 4a and b) . The relative amount of virus within the LNCaP tumor mass was found to be sevenfold higher at late stage of viral infection as compared to the input virus, supporting the conclusion that the amplicon was able to complement the replication deficiency in ICP4 À virus in tumor mass. Together, these results indicate that killing of the tumor cells was a result of viral replication rather than mere cytotoxicity of the virus (Figure 4c) .
With respect to toxicity, the CMV-ICP4 amplicon/ helper virus exhibited high levels of toxicity to the treated mice, causing skin lesions, severe hemorrhage in the stomach, and death of all mice within 10 days after the second viral injection. By comparison, the ARR 2 PB-ICP4 amplicon/helper virus was much less toxic to the mice, although some mild stomatitis developed at 10 days after the second viral injection. In order to assess the extent of viral infection to other tissues, histochemical analyses of cross-sections of tumors and normal organs were performed by incubation with X-gal to indicate the presence ICP0, infected-cell protein 0; ND, not determined.
HSV-1 amplicons complement viral replication CY-F Lee et al of the ICP4 À helper virus, which carries the LacZ gene. Beta-galactosidase activity from both the CMV-ICP4 and ARR 2 PB-ICP4 amplicon/helper viruses was found extensively throughout the LNCaP tumor mass with CMV-ICP4 amplicon/helper virus also detected in the normal organs, but not with the ARR 2 PB-ICP4 amplicon/helper virus ( Figure 5) . However, the relatively more sensitive quantitative real-time PCR substantiated CMV-ICP4 amplicon/helper virus histochemical results and revealed a comparatively small amount of the ARR 2 PB-ICP4 amplicon/helper virus present in normal tissues, such as liver and kidney ( Table 1 ). The reduced activity of ARR 2 PB-ICP4 amplicon/helper virus in nonprostate normal tissues was unlikely caused by contamination of wild-type virus created by recombination between the amplicon and helper virus during virus production as we have extensively tested this possibility and demonstrated that it was not the case. More likely, the nonprostate specific viral replication may be attributed to the leakage of ARR 2 PB promoter in the amplicon. Our previous study has shown that HSV-1 ICP0 may interfere with the specificity of some cellular promoters, 33 hence, the ICP0 expressed from the helper virus may override the prostate specificity of the ARR 2 PB promoter to cause low-level expression of ICP4 in some cells, resulting in nonprostate specific replication of the virus. To avoid this risk, it may be necessary to create a helper virus with an ICP0 À backbone, since it has been reported that ICP0 deletion makes the virus capable of replicating in a tumor-specific fashion in some cancer cells. 42 This study provides a proof in principle that a tissuespecific promoter driving an essential viral gene in a separate viral construct can complement a replication deficient virus to restrict oncolytic killing to cancer cells derived from the target tissue. The advantages of this approach compared with using recombinant HSV-1 with an essential gene regulated by a tissue-specific exogenous promoter are that (1) the amplicon/helper system is much easier and versatile to create than recombinant HSV-1 viruses; (2) since the regulatory elements of a tissuespecific promoter is located outside of the viral genome, less interference from the viral genomic structure may be expected for better control of the transgene expression; and (3) since the oncolytic replication of the helper virus is solely dependent on the presence of amplicon, adjusting the ratio of helper to amplicon can determine the potency of the viral stock for the treatment. Since typically a helper/amplicon ratio from three passages is in a range of 1:3-3:1, a final ratio for lytic viral replication (50:1 in the present study) can be easily achievable by diluting the stock with various amounts of pure helper virus. In addition, high helper/amplicon ratios reduce the probability of homologous recombination between the amplicon and helper virus. Although outside the scope of the present investigation, to further eliminate the risk, a hybrid viral system could be used. 43 For instance, an HSV-1 virus with a complete deletion in the ICP4 region may be used to package an adenovirus-associate virus that carries ARR 2 PB-ICP4. In this system, the homologous region will be completely eliminated.
In conclusion, this study demonstrated that prostatespecific expression of the ICP4 essential gene by an amplicon virus was capable of complementing the replication of an ICP4
À helper virus in the LNCaP cells, achieving selective killing of the prostate cancer cells both in vitro and in vivo, and that HSV-1 viral replication could be restricted and regulated by incorporating a tissuespecific or tumor-specific element in front of an essential viral gene to achieve oncolytic selectivity.
